Simcyp Access is a new cloud-based offering from the leading provider of physiologically-based pharmacokinetic (PBPK) modeling and simulation. Simcyp Access is a licensing approach that provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects.
A selection of short essays from our blog containing insights from our thought leaders on how modeling and simulation has impacted and is continuing to reshape our approach to drug development.
The current version of the database includes clinical safety and efficacy information on all biologics as well as newer synthetic DMARDs currently approved or in development for rheumatoid arthritis (RA). Information on older treatment options (MTX and other DMARDs) was included if they are used as active controls.
The current version of the database includes clinical safety and efficacy information on treatment options currently approved or in development for Chronic Kidney Disease (CKD) progression
in patients with Type 2 Diabetes Mellitus (T2DM) and overt albuminuria/proteinuria, as well as patients with IGA nephropathy.
The current version of the database contains information from randomized controlled trails on all current biologic and small molecule drugs that are evaluated for moderate-to-severe Crohn’s disease in patients that failed conventional treatment.
The Quantify AS Clinical Outcomes Database is developed to document clinical safety and efficacy information from randomized controlled trials investigating biologics currently approved or in development for ankylosing spondylitis (AS).
A selection of short essays from our blog, written to empower our customers with modeling and simulation (M&S) and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing and sharing clinical trial results.
Certara Optimize is a strategic and programmatic approach to drug development that leverages our expertise in drug development, clinical pharmacology, the use of quantitative analysis methods, and regulatory science to optimize decision-making.